Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
University of California, Davis
Hoffmann-La Roche
Incyte Corporation
Formation Biologics
Nektar Therapeutics
NGM Biopharmaceuticals, Inc
Numab Therapeutics AG
M.D. Anderson Cancer Center
GeoVax, Inc.
University of Washington
M.D. Anderson Cancer Center
GlaxoSmithKline
NextCure, Inc.
Washington University School of Medicine
SecuraBio
Genmab
Genmab
Baylor College of Medicine
Genmab
University of Washington
Sensei Biotherapeutics, Inc.
Nektar Therapeutics
Ludwig Institute for Cancer Research
Privo Technologies
Incyte Corporation
Incyte Corporation
Eisai Inc.
Seagen Inc.
Pfizer
Dynavax Technologies Corporation
Incyte Corporation
Washington University School of Medicine
University of Texas Southwestern Medical Center
Incyte Corporation
Daiichi Sankyo
Wake Forest University Health Sciences
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
Millennium Pharmaceuticals, Inc.
Ohio State University
Emory University
Case Comprehensive Cancer Center